RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome
YANTAI, China, April 3, 2024 /PRNewswire/ -- RemeGen Co. Ltd.
RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024
YANTAI, China, March 11, 2024 /PRNewswire/ -- RemeGen Co. Ltd.
World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap
YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd.
RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients
YANTAI, China, Jan. 12, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, announced recently that its independently developed mesothelin (MSLN)-targeting antibody-drug conjugate (ADC), RC88, has been granted Fast Tra...
RemeGen's Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment
YANTAI, China, Dec. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd.
RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients
YANTAI, China, Dec. 18, 2023 /PRNewswire/ -- RemeGen Co. Ltd.
RemeGen Announces Publication of Results from Two Phase II Studies for Disitamab Vedotin in Latest Issue of Journal of Clinical Oncology (JCO)
YANTAI, China, Nov. 28, 2023 /PRNewswire/ -- RemeGen Co. Ltd.
RemeGen to Present Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session at the American College of Rheumatology
YANTAI, China, Nov. 15, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
Remegen's Innovative New Drug Telitacicept(RC18) Obtains Positive Phase III Results, Submitted for Second Indication for Treatment of Rheumatoid Arthritis
YANTAI, China, Sept. 27, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
RemeGen's Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren's Syndrome: Findings Published in Prestigious Rheumatology Journal
YANTAI, China, July 25, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors
The partnership focuses on combining novel antibody-drug conjugates RC88 and
RC108 with a PD-1 inhibitor sintilimab for enhanced treatment outcomes
YANTAI, China, July 10, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer
YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name
The "B" marker is removed from the Company's stock short name
YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
RemeGen Celebrates World Intellectual Property Day 2023
YANTAI, China, April 26, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy
YANTAI, China, Feb. 28, 2023 /PRNewswire/ -- RemeGen Co., Ltd.
RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA
YANTAI, China, Dec. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd.
RemeGen's Disitamab Vedotin Achieves First-Line Treatment Recommendation Status for Advanced Urothelial Cancer in Updated 2022 CSCO Guidelines
YANTAI, China, Nov. 17, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a Chinese commercial-stage biotechnology company, announced onNovember 5 that the Company's self-developed novel antibody-drug conjugate (ADC) Disitamab Vedotin (RC48) has been offi...
RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients
YANTAI, China, Nov.1, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently released data from the Phase II clinical study of its proprietary novel fusion protein Telitacicept for the treatment of myasthenia ...
RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis
YANTAI, China, Oct. 13, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation (ODD) for its proprietary novel fusion prote...
RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China
YANTAI, China, Sept. 19, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently announced the preliminary results of the Phase III confirmatory study of its proprietary novel fusion protein Telitacicept for th...